Corpus Intelligence IC Memo — VIBRA HOSPITAL OF SACRAMENTO 2026-04-26 09:35 UTC
IC Memo — VIBRA HOSPITAL OF SACRAMENTO
Investment Committee Memorandum | CA | 58 beds | Grade D | EBITDA uplift $3.1M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

VIBRA HOSPITAL OF SACRAMENTO

CCN 052033 | SACRAMENTO, CA | 58 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

VIBRA HOSPITAL OF SACRAMENTO is a 58-bed suburban community hospital in SACRAMENTO, CA with $42.4M in net patient revenue and a 4.4% operating margin. The hospital serves a payer mix of 23.9% Medicare, 1.1% Medicaid, and 75.1% commercial.

Thesis: Turnaround. Our ML models identify $3.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 4.4% to 11.8% (+736bps).

Net Revenue HCRIS$42.4M
Current EBITDA COMPUTED$1.9M
Operating Margin COMPUTED4.4%
Occupancy HCRIS84.5%
Revenue / Bed COMPUTED$731K
Net-to-Gross HCRIS21.3%
Distress Probability ML39.0%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
117
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of 4.4% places it above the state median. Among 117 size-comparable peers (29-116 beds), the median margin is -6.1%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (29-116), prioritizing same-state peers. 117 hospitals in the comp set.

HospitalStateBedsRevenueMargin
VIBRA HOSPITAL OF SACRAMENTO (Target)CA58$42.4M4.4%
RANCHO LOS AMIGOS NATL.REHAB.CCA83$512.6M41.9%
USC NORRIS CANCER HOSPITALCA60$468.7M19.1%
KFH - FREMONTCA100$296.2M-6.6%
MERCY HOSPITAL OF FOLSOMCA106$287.8M17.0%
MARSHALL HOSPITALCA111$286.0M-5.9%
LLUMC MURRIETACA111$276.7M-20.3%
ADVENTIST HEALTH SONORACA84$274.3M-7.4%
CPMC-R.K. DAVIES MEDICAL CENTECA105$243.7M24.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.1M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$890K+210bp18mo
Cost to Collect4.5%2.5%$848K+200bp12mo
Denial Rate Reduction12.0%6.5%$840K+198bp12mo
A/R Days Reduction5200.0%3800.0%$516K+122bp9mo
Clean Claim Rate88.0%96.0%$27K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$890K
Cost to Collect
$848K
Denial Rate Reduction
$840K
A/R Days Reduction
$516K
Clean Claim Rate
$27K
Total EBITDA Uplift$3.1M
Current EBITDA$1.9M
+ RCM Uplift+$3.1M
Pro Forma EBITDA$5.0M
Current Margin4.4%
Pro Forma Margin11.8%
WC Released (1x)$1.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$2.9M$43.5M15.19x72.3%
Base (11x exit)10.0x11.0x$2.9M$48.8M17.03x76.3%
Bull Case9.0x11.0x$2.6M$60.0M23.28x87.7%
Bull (12x exit)9.0x12.0x$2.6M$66.2M25.69x91.4%
Bear Case11.0x10.0x$3.2M$27.0M8.56x53.6%
Bear (11x exit)11.0x11.0x$3.2M$30.7M9.74x57.6%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 117 hospitals with 29-116 beds
  • Same-state prioritization (n=118)
  • Comp margins: P25=-21.6% / P50=-6.1% / P75=1.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.